U.S. markets open in 2 hours 4 minutes

Infinity Pharmaceuticals, Inc. (INFI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.0400-0.0700 (-2.25%)
At close: 4:00PM EDT
Sign in to post a message.
  • K
    KevinL
    Buying October $3 calls. @ $1.00. Selling. $8 cover calls October for $ .30. So cost $ .70 Good trading to all
  • p
    paul
    Interesting movement today. Had to add some more to my position
  • J
    Jun
    This stock is going to be amazing stock to position in late June or beginning of July. There are people calling it for 9 - 12. Is this price base on medium or long term holding? Any advise??
  • K
    KevinL
    Someone just purchased 100 call contracts. 4.00. July 16. @ .20. Or. 2000 dollars. Unuasial activity
    Bullish
  • K
    Kenneth
    Definitely looks like there is call activity on the June 4th 4's and then moving to the July 16th's 4's, 5's & 6's which are even heavier. Looks like it is trending higher at this point. Interesting.
  • T
    Thomas
    Appreciate John for noticing the shelf offering by INFI for up to $250 million. A development stage company has several options for raising money. This is one way. Making a deal with another company and sharing future revenues or selling a product outright are other possibilities to raise money. A convertible bond or borrowing are others. The shelf offering is being done presumable because INFI likes their product and wants to control its development and sales. Hope this is the reason and that they have some inkling that the results to be released on July 27 are likely to be good.
    Bullish
  • B
    Bruno
    Potential Acquisitions
    Infinity Pharmaceuticals Files for $250 Million Mixed-Securities Shelf Offering
    05/14/2021

    Infinity Pharmaceuticals (INFI) on Thursday filed a registration statement covering the potential sale of up to $250 million in securities.

    The securities, which may be offered from time to time, include debt securities, common shares, preferred shares, units, and warrants, according to a filing with the US Securities and Exchange Commission.

    Net proceeds from the offering will be used for general corporate purposes, which may include research and development expenses and potential acquisitions.
  • G
    Glenn
    I have a really good feeling about this one.
    Bullish
  • A
    Andy
    So the big question is why did Mark Lampart sell his INFI stock? Obviously he knows more than anyone on this board. No way I would invest with the major shareholder selling his stake
  • j
    jim
    Time to cost down. Accumulate
  • B
    Bruno
    Infinity Pharmaceuticals initiated with a Buy at Truist

    Truist analyst Robyn Karnauskas initiated coverage of Infinity Pharmaceuticals with a Buy rating and $12 price target. The analyst is positive on the company's potential for a "first-in-class" and "best-in-class" oral drug showing strong risk-benefit profile in bladder cancer and breast cancer studies. Karnauskas adds that Infinity's eganelisib is "differentiated" and "underappreciated", with clinical data to date supporting its further development.

    03/18/2021
  • g
    glenn
    A good presentation today by Infi's CEO and CMO at Truist.
  • K
    KevinL
    Sometimes you have to weather the storm, to see the sunshine and brighter days.
    Bullish
  • c
    ceoeli
    up 7% pre market opens in the red?
  • B
    Bruno
    Price Target $12 now; it is time to add.
  • p
    paul
    Mid year results update and FDA guidance in July. Many opportunities for good news
  • m
    mario
    Go infi go!
  • g
    glenn
    why so much volume the last two days?
  • m
    mario
    Glenn, you write comments and that’s fine, but you have no facts to back what you say....i tend not to listen to fiction vs fact. One fact: i dont know Paul at all, just like his comment. Just back what you want to say that’s all!